A more recent study involving 180 stage III CRC patients treated with FOLFOX-4 showed that ERCC1 overexpression is an important predictor of early failure (p = 0.005), DFS (p <0.001), and OS (p < 0.001) [41]. Here, ERCC1 is linked to colorectal carcinoma.